Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
Compass Pathways, a biotechnology company focused on developing innovative treatment options for people living with serious mental health conditions, is set to participate in Psych Congress 2026, scheduled to take place in New Orleans, Louisiana, from September 14 through September 19. During the major psychiatric meeting, the company plans to highlight its ongoing work in treatment-resistant depression (TRD), introduce a new educational initiative for U.S. healthcare professionals, and share new health economics and outcomes research (HEOR) findings.
Compass Pathways will debut “Change the Tune in TRD,” an educational campaign designed specifically for U.S. healthcare professionals. The initiative is intended to provide information about the neurobiology associated with treatment-resistant depression while helping clinicians better understand potential approaches to navigating care pathways for individuals whose depression has not responded adequately to existing treatments.
In addition to the campaign launch, Compass Pathways will present several new HEOR analyses examining the real-world burden associated with TRD. The company will also feature encore presentations from its COMP360 psilocybin clinical development program, including findings from two pivotal Phase 3 studies evaluating COMP360 in people with treatment-resistant depression.
Compass Pathways Expands Focus on Treatment-Resistant Depression
Treatment-resistant depression represents a significant challenge for patients, healthcare professionals, and healthcare systems. Individuals affected by TRD may continue to experience substantial depressive symptoms despite receiving multiple treatment approaches. The condition can create challenges that extend beyond symptoms themselves, potentially affecting quality of life, daily functioning, healthcare utilization, treatment decisions, and overall costs.
Against this backdrop, Compass Pathways is using its presence at Psych Congress 2026 to emphasize the importance of improving understanding of TRD and the challenges associated with identifying and managing the condition in routine clinical practice.
The company’s participation combines education, health economics research, and clinical development data. This approach is designed to address different aspects of the TRD treatment landscape, from recognizing treatment resistance in real-world settings to understanding healthcare resource utilization and evaluating emerging therapeutic approaches.
The company’s new educational campaign is expected to be a central feature of its activities at the conference.
“Change the Tune in TRD” to Support HCP Education
Compass Pathways will officially debut “Change the Tune in TRD,” a new educational initiative developed for U.S. healthcare professionals. The campaign focuses on two key areas: understanding the neurobiology of treatment-resistant depression and navigating care pathways for patients living with the condition.
The initiative will be introduced during a three-panel Innovation Theater session at Psych Congress 2026. The session is scheduled for September 15 from 12:15 p.m. to 1:30 p.m. in Room 220-222.
The panel brings together professionals with experience across psychotherapy, psychiatry, and interventional psychiatry. The featured speakers are Saundra Jain, MA, PsyD, LPC, psychotherapist and adjunct clinical affiliate at the University of Texas at Austin School of Nursing, as well as a practitioner in Austin, Texas; Bryan B. Shapiro, MD, MPH, board-certified psychiatrist and assistant clinical professor of psychiatry at UC Irvine Medical Center; and Sandhya Prashad, MD, interventional psychiatrist and founder and medical director of Sandhya J. Prashad, MD, Houston Ketamine Therapeutics, and Houston TMS Therapeutics.
The multidisciplinary nature of the panel reflects the complexity of depression care and the range of clinical perspectives that can contribute to the management of treatment-resistant depression.
By focusing on neurobiology and care pathways, the campaign is positioned to support broader professional discussion about how TRD is understood and managed in clinical practice. Education can be particularly important in conditions where patients may experience prolonged symptoms and where clinicians must determine appropriate next steps after conventional treatment strategies have not produced sufficient improvement.
New HEOR Research to Examine the Real-World Burden of TRD
Beyond the educational campaign, Compass Pathways will present new research examining the economic and clinical realities surrounding treatment-resistant depression.
Health economics and outcomes research can provide important context for healthcare decision-making by examining how diseases affect healthcare resource utilization, costs, clinical outcomes, and healthcare delivery. For TRD, this type of research can help illustrate the broader consequences of persistent or recurrent depressive illness.
At Psych Congress 2026, Compass Pathways will present four new HEOR-related analyses.
Healthcare Costs and Resource Utilization
One presentation, titled “Real-World Healthcare Costs and Resource Utilization Across Health States Among Patients with Treatment-Resistant Depression,” will be presented by Yechu Hua as poster #186.
The research focuses on healthcare costs and resource utilization across different health states among patients with TRD. Understanding these factors can help demonstrate the wider burden associated with treatment-resistant depression beyond the clinical symptoms experienced by individual patients.
Healthcare utilization can include interactions with healthcare professionals, treatment-related services, hospital-based care, and other resources. Examining these patterns in real-world populations may provide useful information for understanding the demands TRD can place on healthcare systems.
Characterizing Depression Episodes
A second presentation, “Characterization of Depression Episodes to Inform Real-World Health States for Major Depressive Disorder and Treatment-Resistant Depression,” will be presented by Vicki Wing as poster #88.
The analysis examines depression episodes with the goal of informing real-world health states associated with major depressive disorder and treatment-resistant depression. Characterizing episodes can help researchers better understand the progression and burden of depression and establish a more detailed picture of how patients experience the condition over time.
For healthcare researchers, such information can also contribute to the development of models used to evaluate healthcare outcomes and resource utilization.
Provider Perspectives on TRD Management
The third HEOR presentation, “Behavioral Health Provider Perspectives on Management of Individuals with TRD,” will be presented by Caroline Hostetler as poster #95.
This research brings the perspective of behavioral health providers into the discussion surrounding treatment-resistant depression. Clinicians play an important role in identifying patients who may not be responding adequately to treatment and determining how care should evolve when existing approaches are insufficient.
Provider perspectives can also reveal practical challenges encountered in routine clinical settings. These may include treatment decision-making, access to appropriate services, patient engagement, recognition of treatment resistance, and coordination of care.
Identifying TRD in Real-World Practice
The fourth presentation, “Identifying Treatment-Resistant Depression in the Real-World: Clinical Practice and Barriers to Care,” will be presented by Matthew Sidovar as poster #89.
The research examines how treatment-resistant depression is identified in real-world clinical practice and explores barriers that may affect recognition and management of the condition.
Accurate identification of TRD can be an important component of effective care. Patients may undergo multiple treatment attempts, and determining when depression should be considered treatment-resistant can be complex. Real-world barriers may further complicate the process, potentially influencing the timing of treatment changes and access to specialized care.
Together, the four HEOR presentations provide a broad perspective on TRD, addressing healthcare utilization, disease episodes, provider experiences, and real-world identification challenges.
Encore Presentations Highlight COMP360 Clinical Development
Compass Pathways will also present encore data from its COMP360 psilocybin clinical development program at Psych Congress 2026.
The company has been investigating COMP360 as a potential treatment approach for treatment-resistant depression. The conference presentations will include analyses covering participant characteristics, longer-term efficacy and safety, and findings from two pivotal Phase 3 studies.
One presentation, “Demographic and Clinical Characteristics of Participants Receiving COMP360 Psilocybin Treatment for Treatment-Resistant Depression Across Two Pivotal Phase 3 Trials,” will be presented by Kevin Loh as poster #93.
Understanding the demographic and clinical characteristics of participants enrolled in pivotal clinical trials can provide valuable context for interpreting trial results. Such analyses can help describe the populations studied and provide insight into the range of patient characteristics represented across the clinical development program.
Six-Month Efficacy and Safety Data
Another encore presentation will focus on the durability of treatment effects and safety over a longer follow-up period.
Titled “Durability of Efficacy and Safety of COMP360 Psilocybin for Treatment-Resistant Depression Across 26 Weeks in a Double-blind, Randomised, Controlled Phase 3 Study,” the presentation will be delivered by Collin Challis as poster #92.
The 26-week timeframe is significant because evaluating durability can provide additional information beyond the initial treatment period. In clinical development, longer-term follow-up can help researchers understand whether observed effects persist and how safety findings evolve over time.
For a condition such as treatment-resistant depression, where patients may experience persistent or recurring symptoms, understanding the durability of treatment response is an important part of evaluating potential new therapeutic approaches.
Findings From Two Phase 3 Studies
The third COMP360-related presentation is titled “Efficacy and Safety of COMP360 Psilocybin for Treatment-resistant Depression (TRD) in Two Phase 3, Double-blind, Randomized, Controlled Studies.”
The presentation will be delivered by Juliana Gassmann as poster #91.
The inclusion of findings from two pivotal Phase 3 studies provides an opportunity to discuss efficacy and safety data across the broader clinical development program. Randomized, double-blind, controlled studies are designed to provide rigorous comparisons and help researchers evaluate the effects and safety profile of an investigational treatment under controlled conditions.
The presentations at Psych Congress 2026 will therefore give clinicians and other mental health professionals an opportunity to review additional information from the COMP360 program alongside the company’s new research focused on the real-world burden of TRD.
Connecting Clinical Research With Real-World Healthcare Needs
Compass Pathways’ planned presence at Psych Congress 2026 reflects a broader effort to connect clinical development with the practical challenges faced by healthcare professionals and patients.
The four HEOR presentations focus on the real-world environment in which treatment-resistant depression is identified and managed. At the same time, the COMP360 presentations provide clinical development information from pivotal Phase 3 research.
Bringing these areas together can help create a more comprehensive picture of TRD. Clinical trial data can provide evidence about the efficacy and safety of an investigational treatment, while real-world research can offer insight into the burden of disease, healthcare utilization, provider experiences, and barriers to diagnosis and treatment.
The “Change the Tune in TRD” campaign adds another dimension by focusing specifically on professional education.
Importance of Education in TRD Care
Education remains an important element of improving care for complex mental health conditions. Treatment-resistant depression can involve multiple treatment attempts and extended periods of illness, making clinical decision-making particularly challenging.
By developing an educational campaign centered on the neurobiology of TRD and care pathways, Compass Pathways aims to contribute to professional conversations about how clinicians approach patients who continue to experience depression despite treatment.
The Innovation Theater session will also provide an opportunity for experts from different areas of behavioral and interventional mental health care to share perspectives. Their participation underscores the importance of multidisciplinary approaches when addressing complex treatment needs.
Compass Pathways’ participation at Psych Congress 2026 represents a significant opportunity for the company to communicate developments across both its clinical and research programs.The debut of “Change the Tune in TRD” will place healthcare professional education at the center of the company’s conference activities. Meanwhile, the new HEOR research will explore the economic, clinical, and practical burden of treatment-resistant depression in real-world settings.
The company’s encore COMP360 presentations will complement this research by highlighting findings from its clinical development program, including participant characteristics, efficacy and safety outcomes, and durability of treatment effects over 26 weeks.
As mental health care continues to seek new options for people who do not achieve adequate benefit from existing therapies, research into treatment-resistant depression remains an important area of clinical development. By combining educational initiatives, real-world evidence, and clinical trial data, Compass Pathways is using Psych Congress 2026 as a platform to advance discussion around the challenges and potential future approaches to TRD.
The presentations in New Orleans will provide healthcare professionals with an opportunity to engage with new research, review clinical development findings, and explore perspectives on the management of treatment-resistant depression. For Compass Pathways, the conference marks another step in its effort to advance its work in mental health care and support greater understanding of one of the most challenging areas of depression treatment.
Source link: https://ir.compasspathways.com/
